CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 282.5	$ 322.4
Short-term investments	6.3
Accounts receivable, net	348.0	357.2
Inventories	594.6	509.6
Other current assets	175.0	115.1
Total current assets	1,406.4	1,304.3
Property, plant and equipment, net	281.9	270.6
Goodwill	284.7	275.7
Operating lease assets	74.5
Intangibles, net and other long-term assets	302.2	278.0
Total assets	2,349.7	2,128.6
Current liabilities:
Current portion of long-term debt	0.3	18.5
Accounts payable	123.7	104.5
Customer advances	137.9	124.4
Other current liabilities	379.1	351.9
Total current liabilities	641.0	599.3
Long-term debt	493.9	322.6
Operating lease liabilities	55.4
Other long-term liabilities	267.3	279.0
Commitments and contingencies (Note 13)
Redeemable noncontrolling interest	22.0	22.6
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.01 par value 260,000,000 shares authorized, 172,984,419 and 172,634,220 shares issued and 154,661,991 and 156,609,340 shares outstanding at June 30, 2019 and December 31, 2018, respectively	1.7	1.7
Treasury stock, at cost, 18,322,428 and 16,024,880 shares at June 30, 2019 and December 31, 2018, respectively	(501.5)	(401.5)
Accumulated other comprehensive income	15.4	17.0
Other shareholders' equity	1,345.2	1,279.4
Total shareholders' equity attributable to Bruker Corporation	860.8	896.6
Noncontrolling interest in consolidated subsidiaries	9.3	8.5
Total shareholders' equity	870.1	905.1
Total liabilities and shareholders' equity	$ 2,349.7	$ 2,128.6